Supernus Pharmaceuticals (SUPN) Profit After Tax (2011 - 2026)

Supernus Pharmaceuticals (SUPN) has 16 years of Profit After Tax data on file, last reported at -$2.3 million in Q1 2026.

• Profit After Tax for Q1 2026 came in at -$2.3 million, up 80.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$29.0 million (down 146.87% YoY), and the FY2025 annual result was -$38.6 million, down 152.19% from the prior year.
• Profit After Tax climbed to -$2.3 million in Q1 2026 per SUPN's latest filing, from -$4.1 million in the prior quarter.
• Over five years, Profit After Tax peaked at $38.5 million in Q3 2024 and troughed at -$45.1 million in Q3 2025.
• A 5-year average of $5.6 million and a median of $1.7 million in 2022 frame the typical range for Profit After Tax.
• The sharpest annual moves came in 2024 and 2025: Profit After Tax surged 2496.63% in 2024, then sank 9637.9% in 2025.
• A 5-year view of Profit After Tax shows it stood at $25.5 million in 2022, then plunged by 95.39% to $1.2 million in 2023, then soared by 1204.51% to $15.3 million in 2024, then plunged by 126.78% to -$4.1 million in 2025, then soared by 44.14% to -$2.3 million in 2026.
• Business Quant data shows SUPN's Profit After Tax at -$2.3 million in Q1 2026, -$4.1 million in Q4 2025, and -$45.1 million in Q3 2025.